ArticleInternational journal of cardiology. Heart & vasculature2026
Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Ischemic Injury to Arrhythmogenic Substrate: Molecular and Histopathological Insights into Post-Infarction Sudden Cardiac Death.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Established biomarkers are used for risk stratification after STEMI, but their relationship with cardiac magnetic resonance (CMR)-derived infarct characteristics at 30 days remains incompletely understood. Because 30-day CMR reflects an intermediate post-infarction stage between acute myocardial injury and the later chronic infarct state, we evaluated whether baseline high-sensitivity troponin T (hsTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), cellular communication network factor 1 (CCN1), and proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with 30-day CMR parameters. Methods: In this pre-specified CLEVER-ACS substudy, associations between baseline biomarkers and 30-day CMR parameters were assessed using Spearman correlation. Receiver operating characteristic (ROC) analysis with area under the curve (AUC) was performed for associations after median dichotomization. Exploratory analyses assessed associations with relative CMR changes. Results: 56 STEMI patients were analyzed. hsTnT and NT-proBNP showed the strongest association pattern across functional, structural, volumetric, and microvascular 30-day CMR parameters. CCN1 was associated only with left ventricular ejection fraction (LVEF), and PCSK9 showed no significant associations. hsTnT and NT-proBNP showed relevant discriminatory performance for parameters including LVEF (AUC 0.79, 95% CI 0.67-0.91, and 0.81 [0.69-0.93]), left ventricular scar (0.87 [0.77-0.96] and 0.76 [0.63-0.89]), scar mass (0.84 [0.74-0.95] and 0.79 [0.67-0.91]), and microvascular obstruction (0.72 [0.56-0.87] and 0.71 [0.55-0.86]), respectively. Exploratory analyses linked only hsTnT and NT-proBNP to changes in CMR parameters. Conclusions: Baseline hsTnT and NT-proBNP showed strong associations with 30-day CMR parameters after STEMI, whereas CCN1 and PCSK9 provided no discriminatory value in this intermediate post-infarction stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.